AXSMHealthcare · BiotechnologyThe 22 Wall Street analysts covering Axsome Therapeutics, Inc. hold a median 12-month price target of $275 — +100.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 68 of 100 as at 3 Nov 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Axsome Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (94): The business earns solid, repeatable profits on what it owns.
Issuance (35): The company has been issuing shares or taking on financing, diluting existing holders.
Size (18): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on AXSM, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +100.8% from it.
Of the 20 most recent actions, 3 moved their price target up and 8 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 3 Nov 2026 | Baird | Maintains | Outperform | $246 → $220 |
| 3 Nov 2026 | Guggenheim | Maintains | Buy | $275 → $250 |
| 3 Nov 2026 | Morgan Stanley | Maintains | Equal-Weight | $247 → $249 |
| 3 Nov 2026 | RBC Capital | Maintains | Outperform | $295 → $273 |
| 3 Nov 2026 | UBS | Maintains | Buy | $256 → $239 |
| 26 Oct 2026 | Piper Sandler | Maintains | Overweight | $258 → $238 |
| 8 Oct 2026 | RBC Capital | Maintains | Outperform | $297 → $295 |
| 8 Oct 2026 | RBC Capital | Maintains | Outperform | — |
| 29 Sept 2026 | Deutsche Bank | Maintains | Buy | — |
| 29 Sept 2026 | Deutsche Bank | Maintains | Buy | $280 → $267 |
| 25 Sept 2026 | Morgan Stanley | Maintains | Equal-Weight | — |
| 25 Sept 2026 | Morgan Stanley | Maintains | Equal-Weight | $251 → $247 |
| 23 Sept 2026 | Truist Securities | Maintains | Buy | $200 → $285 |
| 23 Sept 2026 | Truist Securities | Maintains | Buy | — |
| 18 Sept 2026 | Piper Sandler | Reiterates | Overweight | $258 |
| 18 Sept 2026 | Piper Sandler | Reiterates | Overweight | — |
| 31 Aug 2026 | HC Wainwright & Co. | Reiterates | Buy | $290 |
| 31 Aug 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 12 Aug 2026 | Mizuho | Maintains | Outperform | $306 → $316 |
| 12 Aug 2026 | Mizuho | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
AXSM appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Axsome Therapeutics, Inc. returned +1.5% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 98% of US stocks
Cheaper than 15% of US stocks
Cheaper than 2% of US stocks
Cheaper than 94% of US stocks
Higher than 86% of US stocks
Higher than 73% of US stocks
Higher than 98% of US stocks
Higher than 27% of US stocks
Higher than 16% of US stocks
Higher than 8% of US stocks
Higher than 24% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Axsome Therapeutics, Inc. has a market value of $7.1B and an enterprise value of $7.1B.
Revenue in the twelve months to 30 June 2026: $776.6M. The latest quarter grew 51.9% year on year.
Net income over the same four quarters: −$191.6M, a −24.7% net margin.
Diluted earnings per share, trailing twelve months: $−3.75.
Free cash flow in the twelve months to 30 June 2026: −$72.0M.
Trailing P/E: −38.3×; forward P/E: 34.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Axsome Therapeutics, Inc. employs 925 people — $840K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Axsome Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
The Motley Fool highlighted Axsome’s 52% year-over-year third-quarter revenue growth to $260 million and management’s expectation that Auvelity could reach $8 billion in peak annual revenue.
Why it matters — These figures and the stated Auvelity revenue expectation are relevant to investors tracking Axsome’s commercial performance and management outlook.
Axsome Therapeutics announced it will participate in four investor conferences in November 2026, including fireside chats at the Guggenheim and UBS conferences and investor meetings at the Wolfe Research and Truist events.
Why it matters — The announcement provides AXSM watchers with dates and formats for upcoming opportunities to hear from or meet with the company.
Seeking Alpha upgraded Axsome Therapeutics to Hold, saying its valuation better reflects commercial realities following ADA approval. The article notes slower-than-hoped AUVELITY growth in ADA scripts and says Q3’s technical beat benefited from one-time items and improved gross-to-net rather than sustainable volume growth.
Why it matters — AXSM watchers may care because the article points to slower ADA uptake and questions the durability of reported sales growth.
Seeking Alpha published a transcript of Axsome Therapeutics, Inc.’s Q3 2026 earnings call. The provided excerpt contains only the headline and does not include details from the call.
Why it matters — AXSM watchers can note that a Q3 2026 earnings-call transcript is available, but the excerpt provides no information about the company’s reported results or commentary.
Axsome Therapeutics reported third-quarter revenue growth of 52% year over year, driven primarily by continued expansion of AUVELITY sales in major depressive disorder and Alzheimer's disease agitation.
Why it matters — AXSM watchers may note the reported revenue growth and the product sales areas identified as its primary drivers.
The 22 Wall Street analysts covering Axsome Therapeutics, Inc. have a median 12-month price target of $275, with estimates ranging from $238 to $380. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 22 analysts covering Axsome Therapeutics, Inc., 21 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Axsome Therapeutics, Inc. 68 out of 100 across roughly 4,600 US stocks as at 3 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 3 Nov 2026, Axsome Therapeutics, Inc. ranks 68 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (94 of 100).
No one can know that. What the data says: the median 12-month target from 22 analysts implies +100.8% from the last close, and Ticker Nerd's factor model ranks Axsome Therapeutics, Inc. 68 out of 100 as at 3 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Axsome Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AXSM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $238 to $380 over the next 12 months.
Axsome Therapeutics, Inc. returned +1.5% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Axsome Therapeutics Inc. is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders.
The most recent item we track (The Motley Fool, 4 Nov 2026): "Axsome: 3 Key Takeaways for Long-Term Investors". The Motley Fool highlighted Axsome’s 52% year-over-year third-quarter revenue growth to $260 million and management’s expectation that Auvelity could reach $8 billion in peak annual revenue.
Axsome Therapeutics Inc. is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders. Its marketed products include Auvelity for major depressive disorder, Sunosi for excessive daytime sleepiness related to narcolepsy or obstructive sleep apnea, and Symbravo for the acute treatment of migraine. The company also maintains a neuroscience pipeline spanning additional neurological and psychiatric conditions, reflecting its emphasis on disorders with limited treatment options. Axsome Therapeutics Inc. plays a specialized role in the healthcare market by combining commercial products with ongoing clinical development in psychiatry, sleep medicine, pain, and migraine care. Based in New York, the company is positioned as a focused CNS innovator serving patients, physicians, and healthcare systems with therapies designed to address unmet medical needs.
CEO Dr. Herriot Tabuteau M.D. · 925 employees · United States · https://www.axsome.com
